He was 86 when this article was written and is 93

Quote:

---

He was 86 when this article was written and is 93 today. Despite his age, I'd suggest that between the GBM study and the Alzheimer's trial, Dr. Parviz Lalezari should have all the bases covered and questions answered regarding leronlimab's capacity of crossing the blood brain barrier, BBB.
https://www.reddit.com/r/Livimmune/comments/1...amic_view/

I have been pondering the mention of a pilot study in Alzheimer's. As careful as Cytodyn is in it's release of news I don't think they'd mention it unless they have a green light from the FDA. Generally pre-clinical would need to be done first. With the safety profile of leronlimab established and the standing of Dr. Parviz Lalezari in the research community it's likely leronlimab can skip that step.

Leronlimab would still have to do a phase 2 after the pilot study. Though with success in that and the results from the pilot study it is possible that the FDA could give a preliminary approval. As we've seen the FDA wants to see some progress in that space even if it's underwhelming.

---